ABI
BIIB icon

Adamant Biomedical Investments’s Biogen BIIB Stock Holding History

Adamant Biomedical Investments’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$18.1M Sell
53,250
-1,770
-3% -$573K 4.32% 2
2014
Q3 		$18.2M Buy
+55,020
New +$18.1M 4.54% 3

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Adamant Biomedical Investments's BIIB Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its Biogen (BIIB) stake by 3.2% in Q4 2014, selling an estimated $573K and leaving 53,250 shares worth $18.1M. The position accounts for 4.32% of the portfolio, ranked #2.

Adamant Biomedical Investments first reported a position in BIIB in Q3 2014 and has held it in 2 quarters since. The position peaked at $18.2M in Q3 2014. 884 funds tracked by Wall St. Rank hold BIIB as of Q4 2014.

  • Adamant Biomedical Investments held 53,250 shares of Biogen worth $18.1M as of Q4 2014.
  • Adamant Biomedical Investments sold 1,770 Biogen shares in Q4 2014, an estimated $573K.
  • Biogen made up 4.32% of Adamant Biomedical Investments's portfolio in Q4 2014, its #2 holding.
  • Adamant Biomedical Investments first reported a position in Biogen in Q3 2014 and has held it in 2 quarters since.
  • Adamant Biomedical Investments's Biogen position peaked at $18.2M in Q3 2014.
  • 884 funds tracked by Wall St. Rank held Biogen as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.